Apogee Therapeutics (APGE) director Lisa Bollinger granted 7,657 stock options

Rhea-AI Filing Summary

Apogee Therapeutics director Lisa Bollinger received a stock option grant for 7,657 shares of common stock on June 9, 2026. The option has an exercise price of $85.00 per share and expires on June 9, 2036. All 7,657 options will vest on the one-year anniversary of the grant date, contingent on her continued service, and represent her total option holdings reported in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bollinger Lisa

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	7,657	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 7,657 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 7,657 options Exercise price: $85.00 per share Expiration date: June 9, 2036 +2 more

5 metrics

Options granted 7,657 options Stock option grant on June 9, 2026

Exercise price $85.00 per share Strike price for stock options

Expiration date June 9, 2036 Option term end

Underlying shares 7,657 shares Common stock underlying option grant

Post-grant option holdings 7,657 options Total options held after transaction

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vest, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 85.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-09T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest financial

"will vest on the one-year anniversary of the grant date"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bollinger Lisa

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$85	06/09/2026		A		7,657		(1)	06/09/2036	Common Stock	7,657	$0.00	7,657	D

Explanation of Responses:

1. This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

	/s/ Matthew Batters, as attorney-in-fact for Lisa Bollinger	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Apogee Therapeutics (APGE) report for Lisa Bollinger?

Apogee Therapeutics reported that director Lisa Bollinger received a stock option grant for 7,657 shares. The options are exercisable into common stock at a fixed price and represent a compensation-related award, not an open-market purchase or sale.

What is the exercise price of Lisa Bollinger’s new Apogee Therapeutics (APGE) options?

The granted stock options carry an exercise price of $85.00 per share. This means Bollinger can buy Apogee Therapeutics common stock at $85.00 once the options vest, regardless of the market price at that time.

When do Lisa Bollinger’s Apogee Therapeutics (APGE) stock options vest?

The 7,657 stock options granted to Lisa Bollinger vest on the one-year anniversary of the June 9, 2026 grant date. Vesting is conditioned on her continued service with Apogee Therapeutics through that anniversary date.

When do Lisa Bollinger’s Apogee Therapeutics (APGE) options expire?

Lisa Bollinger’s stock options expire on June 9, 2036. After that expiration date, any unexercised options become worthless and can no longer be used to purchase Apogee Therapeutics common shares at the $85.00 exercise price.

How many Apogee Therapeutics (APGE) options does Lisa Bollinger hold after this grant?

Following this grant, Lisa Bollinger holds 7,657 stock options according to the Form 4. These options are all from this single grant and are subject to a one-year vesting requirement tied to continued service.